Articles Vol. 67 No. 2 02/03/2026

ANALYSIS OF FACTORS ASSOCIATED WITH THE HEART FAILURE TREATMENT COSTS AT LE VAN THINH HOSPITAL

Hoang Thy Nhac Vu1,2,3,4, Le Hong Tuan1,3, Ha Chau Hung2,4, Chung Khang Kiet2,4, Tran Van Khanh1,3
1 Le Van Thinh Hospital
2 University of Medicine and Pharmacy at Ho Chi Minh City
3 Bệnh viện Lê Văn Thịnh
4 Đại học Y Dược thành phố Hồ Chí Minh
DOI: 10.52163/yhc.v67i2.4361
22 Views
34 Downloads
Abstract

Objective: To identify factors associated with the treatment costs of heart failure at Le Van Thinh Hospital.

Methods: A cross-sectional descriptive study was conducted using retrospective data from 2,386 treatment episodes of heart failure in 2024. Multivariate linear regression analysis was applied to determine cost-related factors, with the dependent variable being the total treatment cost per episode (log-transformed). Independent variables included age, sex, type of treatment, length of stay, and specific health conditions (atrial fibrillation, stent placement, diabetes mellitus, chronic kidney disease).

Results: The study sample consisted of 2,226 outpatient episodes (93.2%) and 160 inpatient episodes (6.8%). The mean cost per outpatient treatment was 794,000 ± 321,000 VND, while the median cost per inpatient treatment was 5,353,000 VND. Medications accounted for 85.8% of outpatient costs and 37.8% of inpatient costs. The multivariate linear regression model (R² = 0.847) indicated that higher costs were associated with inpatient treatment (+179.4%), stent placement (+16.5%), heart failure with type 2 diabetes (+30.3%), and each additional day of hospitalization (+21.9%).

Conclusion: Treatment costs of heart failure can be estimated based on patients’ specific health conditions, which may support financial planning and cost management.

References
[1]
Ponikowski P, Voors A.A, Anker S.D et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J.37, 2016, 27: 2129-2200. Google Scholar
[2]
Groenewegen A, Rutten F.H, Mosterd A, Hoes A.W. Epidemiology of heart failure. Eur J Heart Fail, 2020, 22 (8): 1342-1356. Google Scholar
[3]
Bộ Y tế. Báo cáo thống kê y tế năm 2023. Nhà xuất bản Y học, Hà Nội, 2023. Google Scholar
[4]
Kilgore M, Patel H.K, Kielhorn A et al. Economic burden of hospitalizations of medicare beneficiaries with heart failure. Risk Manag Healthc Policy, 2017, 10: 63-70. Google Scholar
[5]
Lesyuk W, Kriza C, Kolominsky-Rabas P. Cost-of-illness studies in heart failure: a systematic review 2004-2016. BMC Cardiovasc Disord, 2018, 18 (1): 74. Google Scholar
[6]
Savarese G, Lund L.H. Global public health burden of heart failure. Card Fail Rev, 2017, 3 (1): 7-11. Google Scholar
[7]
Reed B.N, Sueta C.A, O’Connor C.M. Heart failure clinical trials and health economics: a review and considerations for the future. Expert Rev Pharmacoecon Outcomes Res, 2020, 20 (1): 29-36. Google Scholar
[8]
Nguyễn Văn Điển, Phạm Nguyễn Vinh, Đỗ Kim Quế. Chi phí điều trị suy tim cấp tại Bệnh viện Bạch Mai. Tạp chí Tim mạch học Việt Nam, 2019, 88: 45-52. Google Scholar
[9]
Toàn Thị Ngọc Ánh, Nguyễn Văn Kiên, Lê Thị Mai. Phân tích chi phí điều trị ngoại trú bệnh nhân suy tim tại ba bệnh viện tuyến tỉnh. Tạp chí Y học thực hành, 2023, 1178 (5): 67-73. Google Scholar
[10]
McMurray J.J.V, Solomon S.D, Inzucchi S.E et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med, 2019, 381 (21): 1995-2008. Google Scholar